A5055324214- SARS-CoV-2 and COVID-19 Research
- Inhalation and Respiratory Drug Delivery
- Protein purification and stability
- Microencapsulation and Drying Processes
- RNA Interference and Gene Delivery
- Animal Virus Infections Studies
- Vaccine Coverage and Hesitancy
- Drug Solubulity and Delivery Systems
- Innovative Microfluidic and Catalytic Techniques Innovation
- Tuberculosis Research and Epidemiology
- Advanced Drug Delivery Systems
- Influenza Virus Research Studies
- Pneumonia and Respiratory Infections
- Hepatitis B Virus Studies
- interferon and immune responses
- Granular flow and fluidized beds
- Environmental Sustainability and Education
- Pneumocystis jirovecii pneumonia detection and treatment
- Muscle activation and electromyography studies
- Mosquito-borne diseases and control
- Microfluidic and Bio-sensing Technologies
- Conducting polymers and applications
- Advanced biosensing and bioanalysis techniques
- Health, Education, and Aging
- Safe Handling of Antineoplastic Drugs
Access to Wholistic and Productive Living Institute
2022-2025
Access to Advanced Health Institute
2022-2025
Infectious Disease Research Institute
2020-2022
Seattle University
2022
University of Colorado Boulder
2012-2015
Univates
2014
Current RNA vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are limited by instability of both the and lipid nanoparticle delivery system, requiring storage at -20°C or -70°C compromising universally accessible vaccine distribution. This study demonstrates thermostability adaptability a nanostructured carrier (NLC) system for that has potential to address these concerns. Liquid NLC alone is stable refrigerated temperatures ≥1 year, enabling stockpiling rapid...
mRNA vaccines were the first to be authorized for use against SARS-CoV-2 and have since demonstrated high efficacy serious illness death. However, limitations in these been recognized due their requirement cold storage, short durability of protection, lack access low-resource regions. We developed an easily-manufactured, potent self-amplifying RNA (saRNA) vaccine that is stable at room temperature. This saRNA formulated with a nanostructured lipid carrier (NLC), providing stability, ease...
Seasonal and pandemic influenzas are continuous threats to human health, requiring rapid development of vaccines multiple evolving viral strains. New RNA vaccine technologies have the adaptability manufacturability facilitate preparedness but limited flexibility in their route administration, reducing ability establish local protective immune responses such as respiratory mucosal immunity. Here, we describe monovalent bivalent self-amplifying (saRNA) against A/Vietnam/1203/2004 H5N1...
Background: Dry powders offer the potential to increase stability and reduce cold-chain requirements associated with distribution of vaccines other thermally sensitive products. The Alberta Idealized Nasal Inlet (AINI) is a representative geometry for in vitro characterization nasal products that may prove useful examining intranasal delivery powders. Methods: Spray-dried trehalose were loaded at 10, 20, 40 mg doses into active single-dose devices. Primary particle sizes (∼Dv50 = 10 µm...
Introduction: Yellow fever (YFV) and Zika (ZIKV) viruses cause significant morbidity mortality, despite the existence of an approved YFV vaccine development multiple ZIKV candidates to date. New technologies may improve access vaccines against these pathogens. We previously described a nanostructured lipid carrier (NLC)-delivered self-amplifying RNA (saRNA) platform with excellent thermostability immunogenicity, appropriate for prevention tropical infectious diseases. Methods: prM-E...
Objective. The goal of this study was to assess the electrochemical properties boron-doped diamond (BDD) electrodes in relation conventional titanium nitride (TiN) through vitro and vivo measurements. Approach. Electrochemical impedance spectroscopy, cyclic voltammetry voltage transient (VT) measurements were performed after immersion a 5% albumin solution subcutaneous implantation rats for 6 weeks. Main results. In contrast TiN electrodes, capacitance BDD not significantly reduced solution....
Converting a vaccine into thermostable dry powder is advantageous as it reduces the resource burden linked with cold chain and provides flexibility in dosage administration through different routes. Such presentation may be especially useful development of towards respiratory infectious disease tuberculosis (TB). This study assesses immunogenicity protective efficacy spray-dried ID93+GLA-SE, promising TB candidate, against Mycobacterium (Mtb) murine model when administered via Four routes...
Introduction: Since their introduction, adjuvanted recombinant subunit vaccines against COVID-19 have played a pivotal role in protecting global populations. Optimizing the immune response’s quality, amplitude, and durability to these depends on appropriate adjuvant choice dose combination with selected antigen. Methods: Here, we employed preclinical mouse model study adaptive humoral cellular responses SARS-CoV-2 receptor binding domain (RBD) antigen formulated one of four different...
Abstract Current RNA vaccines against SARS-CoV-2 are limited by instability of both the and lipid nanoparticle delivery system, requiring storage at −20°C or −70°C compromising universally accessible vaccine distribution. This study demonstrates thermostability adaptability a nanostructured carrier (NLC) system for use in pandemic preparedness response. Liquid NLC is stable refrigerated temperatures ≥ 1 year, enabling stockpiling rapid deployment point-of-care mixing with any RNA....
Promising clinical efficacy results have generated considerable enthusiasm for the potential impact of adjuvant-containing subunit tuberculosis vaccines. The development a thermostable vaccine formulation could significant benefits on both cost and feasibility global distribution. candidate ID93 + GLA-SE has reached Phase 2 testing, demonstrating safety immunogenicity as two-vial point-of-care mixture. Earlier publications detailed efforts to develop lead single-vial lyophilized formulation....
With the recent exception of coronavirus disease 2019 (COVID-19), tuberculosis (TB) causes more deaths globally than any other infectious disease, and approximately 1/3 world's population is infected with Mycobacterium (Mtb). However, encouraging progress in TB vaccine development has been reported, 50% efficacy achieved Phase 2b clinical testing an adjuvanted subunit candidate. Nevertheless, current lead candidates require cold-chain transportation storage. In addition to temperature...
ABSTRACT mRNA vaccines were the first to be authorized for use against SARS-CoV-2 and have since demonstrated high efficacy serious illness death. However, limitations in these been recognized due their requirement cold storage, short durability of protection, lack access low-resource regions. We developed an easily-manufactured, potent self-amplifying RNA (saRNA) vaccine that is stable at room temperature. This saRNA formulated with a nanostructured lipid carrier (NLC), providing enhanced...
Dozens of vaccines have been approved or authorized internationally in response to the ongoing SARS-CoV-2 pandemic, covering a range modalities and routes delivery. For example, mucosal delivery via intranasal (i.n.) route has shown improve protective responses comparison intramuscular (i.m.) As we gain knowledge limitations existing vaccines, it is interest understand if changes product presentation combinations multiple vaccine can further immunological outcomes.
Abstract While mRNA vaccines have been effective in combating SARS-CoV-2, waning of vaccine-induced antibody responses and lack respiratory tract immunity contribute to ongoing infection transmission. In this work, we compare contrast intranasal (i.n.) intramuscular (i.m.) administration a SARS-CoV-2 self-amplifying RNA (saRNA) vaccine delivered by nanostructured lipid carrier (NLC). Both i.m. i.n. induce potent systemic serum neutralizing antibodies, bone marrow-resident IgG-secreting...